Tscan Therapeutics, Inc.(TCRX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TCRX Tscan Therapeutics, Inc.

休市中 09-11 16:00:00 EDT

0.3204

+0.0025

+0.79%

盘后0.3268

+0.0064+2.00%

18:27 EDT

最高0.3250	最低0.3055	成交量87.31万
今开0.3242	昨收0.3179	日振幅6.13%
总市值2,172万	流通市值1,853万	总股本6,778万
成交额27.60万	换手率1.51%	流通股本5,782万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TCRX","market":"US","secType":"STK","nameCN":"Tscan Therapeutics, Inc.","latestPrice":0.3204,"timestamp":1789156800000,"preClose":0.3179,"halted":0,"volume":873124,"hourTrading":{"tag":"盘后","latestPrice":0.3268,"preClose":0.3204,"latestTime":"18:27 EDT","volume":10940,"amount":3575.0798,"timestamp":1789165630117,"change":0.0064,"changeRate":0.019975,"amplitude":0.019975},"delay":0,"changeRate":0.007864108210128978,"floatShares":57818600,"shares":67779255,"eps":-0.9,"marketStatus":"休市中","change":0.0025,"latestTime":"09-11 16:00:00 EDT","open":0.3242,"high":0.325,"low":0.3055,"amount":276049.97469896,"amplitude":0.06134,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.9,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1626408000000,"exchange":"NASDAQ","adjPreClose":0.3179,"preHourTrading":{"tag":"盘前","latestPrice":0.325,"preClose":0.3179,"latestTime":"09:18 EDT","volume":1765,"amount":572.758032,"timestamp":1789132732053,"change":0.0071,"changeRate":0.022334,"amplitude":0.018559},"postHourTrading":{"tag":"盘后","latestPrice":0.3268,"preClose":0.3204,"latestTime":"18:27 EDT","volume":10940,"amount":3575.0798,"timestamp":1789165630117,"change":0.0064,"changeRate":0.019975,"amplitude":0.019975},"volumeRatio":0.5586925201477434},"requestUrl":"/m/hq/s/TCRX/tweets","defaultTab":"tweets","newsList":[{"id":"1169717289","title":"TScan Therapeutics预计重组费用绝大部分将转化为未来现金支出","url":"https://stock-news.laohu8.com/highlight/detail?id=1169717289","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169717289?lang=zh_cn&edition=full","pubTime":"2026-09-02 19:25","pubTimestamp":1788348309,"startTime":"0","endTime":"0","summary":"TScan Therapeutics公司表示，预计其重组相关费用中绝大部分都将转化为未来的实际现金支出。这一预期表明，该公司在推进重组计划时，将面临相应的现金流出压力。值得注意的是，并非所有重组费用都会即刻产生现金影响，但TScan Therapeutics认为其中大部分将最终体现为现金支出。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TCRX","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102304901","title":"TScan Therapeutics因资金不足暂停TSC-101的Alloha-2三期研究入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1102304901","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102304901?lang=zh_cn&edition=full","pubTime":"2026-09-02 19:03","pubTimestamp":1788347004,"startTime":"0","endTime":"0","summary":"TScan Therapeutics宣布，由于资金不足以支撑后续进程，该公司已决定暂停其核心候选药物TSC-101所涉及的Alloha-2三期临床研究的患者入组工作。这一战略调整反映出公司在当前融资环境下面临的严峻挑战，同时也凸显了生物技术企业在推进后期临床试验时所遭遇的资金压力。此举或将对该项目的整体时间表产生深远影响，市场亦密切关注其后续资金筹措动向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","TCRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132001275","title":"TScan Therapeutics战略重组，预计至2027年底节省成本5500万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1132001275","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132001275?lang=zh_cn&edition=full","pubTime":"2026-09-02 19:00","pubTimestamp":1788346841,"startTime":"0","endTime":"0","summary":"TScan Therapeutics宣布了一项战略重组计划，预计到2027年底将实现5500万美元的成本节约。这一举措旨在优化运营效率，并进一步巩固公司在细胞治疗领域的竞争地位。重组涉及对现有资源进行重新配置，以确保长期增长目标的实现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TCRX","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192416297","title":"TScan Therapeutics披露：安进将终止与其研究合作及许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1192416297","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192416297?lang=zh_cn&edition=full","pubTime":"2026-08-19 05:04","pubTimestamp":1787087050,"startTime":"0","endTime":"0","summary":"值得注意的是，安进作为全球领先的生物制药公司，此举无疑将对TScan Therapeutics的研发管线及未来战略布局产生深远影响。TScan Therapeutics方面表示，将仔细评估这一变化对公司在研项目及整体运营带来的潜在影响。对于TScan Therapeutics而言，此番变故或许意味着需要重新校准其研发路径，并探索新的合作机会或资金来源以继续推进其创新疗法的开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1057294990.SGD","IE00BJJMRZ35.SGD","LU0320765992.SGD","BIB","LU0868494617.USD","LU1571399168.USD","BBH","BK4585","LU0109394709.USD","IE00B4R5TH58.HKD","LU0058720904.USD","IE0009355771.USD","BK4534","BK4533","LU2242652126.USD","PJP","BK4139","BK4581","LU1983299246.USD","BK4599","IE00BFTCPJ56.SGD","SG9999001440.SGD","LU2242646821.SGD","IE00BJT1NW94.SGD","LU0289739699.SGD","LU2112291526.USD","TBXU","TCRX","AMGN","IE0002141913.USD","LU1061106388.HKD","LU1023059063.AUD","PBE","IBB","LU0889565916.HKD","IBBQ","BK4566","BK4588","IE00B2B36J28.USD","BK4539","LU0122379950.USD","LU2468319806.SGD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198799848","title":"TScan Therapeutics宣布：关键性III期试验Alloha-2™完成首例患者给药，评估Tsc-101治疗血液恶性肿瘤效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1198799848","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198799848?lang=zh_cn&edition=full","pubTime":"2026-07-29 19:02","pubTimestamp":1785322936,"startTime":"0","endTime":"0","summary":"TScan Therapeutics公司正式宣告，其针对血液恶性肿瘤的III期关键性试验Alloha-2™已完成首例患者给药。该试验旨在评估核心候选药物Tsc-101的疗效与安全性，这标志着公司在血液肿瘤治疗领域迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","TCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144235777","title":"TScan Therapeutics有望本月启动Tsc-101三期Alloha-2研究首位患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1144235777","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144235777?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:06","pubTimestamp":1782126415,"startTime":"0","endTime":"0","summary":"TScan Therapeutics在推进其核心候选药物Tsc-101的临床开发方面取得关键进展。公司宣布，计划于本月内启动针对该药物的三期Alloha-2临床试验，并完成首位患者的入组工作。这项名为Alloha-2的研究是Tsc-101开发路径上的重要里程碑。该试验旨在进一步评估Tsc-101在特定适应症中的疗效与安全性。成功启动患者入组标志着公司临床运营按既定时间表顺利推进，也意味着其管线资产向潜在商业化目标又迈出了实质性的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TCRX","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183684147","title":"TScan Therapeutics公布Alloha™一期研究C组初步积极数据，评估Tsc-101在异基因造血细胞移植血癌患者中的疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1183684147","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183684147?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:00","pubTimestamp":1782126018,"startTime":"0","endTime":"0","summary":"TScan Therapeutics近日公布了其正在进行的Alloha™一期临床试验中C组患者的初步积极数据。该研究旨在评估候选疗法Tsc-101在接受异基因造血细胞移植的血癌患者中的安全性与有效性。\n初步结果显示，Tsc-101在这一患者群体中表现出令人鼓舞的临床活性与可管理的安全性特征。这些早期数据为后续开发提供了重要支持，表明该疗法在改善患者预后方面具有潜力。\n公司将继续推进该项研究，并计划在未来分享更全面的临床结果。这一进展标志着TScan在针对血液恶性肿瘤的创新细胞疗法领域迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","TCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115843288","title":"Cellares与TScan Therapeutics达成协议 评估Tsc-101自动化生产用于血液恶性肿瘤患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1115843288","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115843288?lang=zh_cn&edition=full","pubTime":"2026-06-03 21:19","pubTimestamp":1780492780,"startTime":"0","endTime":"0","summary":"Cellares与TScan Therapeutics公司宣布，双方已签署一项合作协议，旨在评估针对血液恶性肿瘤患者的Tsc-101疗法的自动化生产工艺。该协议将聚焦于利用Cellares的自动化制造平台，对TScan的Tsc-101候选产品进行生产流程的优化与评估。Tsc-101是TScan Therapeutics公司开发的一款针对特定靶点的T细胞受体疗法，目前正处于临床研究阶段，拟用于治疗血液系统恶性肿瘤。此次与Cellares在自动化制造方面的合作，有望进一步推动该疗法的开发与未来商业化生产。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","TCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518220126","title":"Tscan Therapeutics, Inc.盘中异动 股价大跌5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518220126","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518220126?lang=zh_cn&edition=full","pubTime":"2025-03-11 01:49","pubTimestamp":1741628968,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日01时49分，Tscan Therapeutics, Inc.股票出现波动，股价急速下跌5.30%。Tscan Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.82%。其相关个股中，Aeon Biopharma, Inc.、Mineralys Therapeutics, Inc.、Checkpoint Therapeutics, Inc.涨幅较大，Aeon Biopharma, Inc.、Biodexa Pharmaceuticals Plc、Scisparc Ltd.较为活跃，换手率分别为5466.60%、3825.64%、991.14%，振幅较大的相关个股有Aeon Biopharma, Inc.、Protagenic Therapeutics Inc C/Wts 29/04/2026 、Biodexa Pharmaceuticals Plc，振幅分别为90.44%、88.14%、58.34%。Tscan Therapeutics, Inc.公司简介：TScan Therapeutics Inc 是一家生物制药公司，专注于开发用于治疗癌症患者的 T 细胞受体  工程化 T 细胞疗法 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311014928abf35ac8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311014928abf35ac8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","TCRX","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518748289","title":"Tscan Therapeutics, Inc.2024财年实现净利润-1.27亿美元，同比减少42.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518748289","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518748289?lang=zh_cn&edition=full","pubTime":"2025-03-10 00:00","pubTimestamp":1741536046,"startTime":"0","endTime":"0","summary":"3月10日，Tscan Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-1.27亿美元，同比减少42.34%；其中营业收入为2.82百万美元，同比减少86.60%，每股基本收益为-1.14美元。从资产负债表来看，Tscan Therapeutics, Inc.总负债1.30亿美元，其中短期债务4.57百万美元，资产负债比为2.86，流动比率为0.09。机构评级：截至2025年3月10日，当前有7家机构对Tscan Therapeutics, Inc.目标价做出预测，其中目标均价为10.29美元，其中最低目标价为3.00美元，最高目标价为15.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000113a268980a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000113a268980a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","TCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517443609","title":"Tscan Therapeutics, Inc.盘中异动 股价大跌5.45%报1.91美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517443609","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517443609?lang=zh_cn&edition=full","pubTime":"2025-03-06 00:43","pubTimestamp":1741193030,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日00时43分，Tscan Therapeutics, Inc.股票出现异动，股价快速下挫5.45%。Tscan Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.04%。其相关个股中，Chimerix, Inc.、Nutriband Inc C/Wts 、Celularity Inc.涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为912.60%、299.54%、282.78%，振幅较大的相关个股有Nkgen Biotech, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 ，振幅分别为82.59%、54.27%、41.26%。Tscan Therapeutics, Inc.公司简介：TScan Therapeutics Inc 是一家生物制药公司，专注于开发用于治疗癌症患者的 T 细胞受体  工程化 T 细胞疗法 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306004351abe9d8d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306004351abe9d8d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4539","TCRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517310944","title":"Needham：维持TScan Therapeutics(TCRX.US)评级，由买入调整至买入评级, 目标价由11.00美元调整至9.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517310944","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517310944?lang=zh_cn&edition=full","pubTime":"2025-03-06 00:41","pubTimestamp":1741192881,"startTime":"0","endTime":"0","summary":"Needham：维持TScan Therapeutics(TCRX.US)评级，由买入调整至买入评级, 目标价由11.00美元调整至9.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06004148550592.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["TCRX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158846313","title":"TScan Therapeutics 2024年第四季度每股收益$(0.30)未达预期$(0.27)，销售额$66.5万未达预期$135万","url":"https://stock-news.laohu8.com/highlight/detail?id=1158846313","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158846313?lang=zh_cn&edition=full","pubTime":"2025-03-05 20:15","pubTimestamp":1741176918,"startTime":"0","endTime":"0","summary":"TScan Therapeutics报告第四季度每股亏损$，未达到分析师一致预期的$，差异为11.11%。与去年同期每股亏损$相比，这是一个42.86%的下降。以上内容来自Benzinga Earnings专栏，原文如下：TScan $Therapeutics$  reported quarterly losses of $ per share which missed the analyst consensus estimate of $ by 11.11 percent. This is a 42.86 percent decrease over losses of $ per share from the same period last year.  The company reported quarterly sales of $665.00 thousand which missed the analyst consensus estimate of $1.35 million by 50.74 percent.  This is a 90.78 percent decre","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","TCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516658010","title":"Tscan Therapeutics, Inc.盘中异动 快速下跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516658010","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516658010?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:41","pubTimestamp":1741016466,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时41分，Tscan Therapeutics, Inc.股票出现异动，股价快速下挫5.00%。Tscan Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.33%。其相关个股中，Bioxcel Therapeutics, Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Entero Therapeutics Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为2303.18%、137.90%、130.65%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Pliant Therapeutics, Inc.，振幅分别为177.97%、70.53%、50.09%。Tscan Therapeutics, Inc.公司简介：TScan Therapeutics Inc 是一家生物制药公司，专注于开发用于治疗癌症患者的 T 细胞受体  工程化 T 细胞疗法 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303234107a25d5714&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303234107a25d5714&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","LENZ","TCRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514382050","title":"Tscan Therapeutics, Inc.盘中异动 急速拉升5.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514382050","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514382050?lang=zh_cn&edition=full","pubTime":"2025-02-28 00:24","pubTimestamp":1740673455,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日00时24分，Tscan Therapeutics, Inc.股票出现异动，股价大幅拉升5.76%。Tscan Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.60%。其相关个股中，Alpha Tau Medical Ltd C/Wts 、Heron Therapeutics, Inc.、Pepgen Inc.涨幅较大，Quoin Pharmaceuticals Ltd、Aeon Biopharma, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为1654.91%、266.46%、112.45%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Quoin Pharmaceuticals Ltd、Pds Biotechnology Corporation，振幅分别为86.14%、47.79%、45.45%。Tscan Therapeutics, Inc.公司简介：TScan Therapeutics Inc 是一家生物制药公司，专注于开发用于治疗癌症患者的 T 细胞受体  工程化 T 细胞疗法 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502280024159632c887&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502280024159632c887&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4139","LENZ","TCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514586274","title":"Tscan Therapeutics, Inc.盘中异动 急速跳水5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514586274","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514586274?lang=zh_cn&edition=full","pubTime":"2025-02-27 04:27","pubTimestamp":1740601670,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日04时27分，Tscan Therapeutics, Inc.股票出现异动，股价快速跳水5.12%。Tscan Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.65%。其相关个股中，Enveric Biosciences, Inc.、Renovaro Inc.、Salarius Pharmaceuticals, Inc.涨幅较大，Enveric Biosciences, Inc.、Aeon Biopharma, Inc.、Organovo Holdings, Inc.较为活跃，换手率分别为6843.34%、332.19%、264.99%，振幅较大的相关个股有Enveric Biosciences, Inc.、Renovaro Inc.、Immatics N V C/Wts 01/07/2025 ，振幅分别为194.07%、81.11%、70.39%。Tscan Therapeutics, Inc.公司简介：TScan Therapeutics Inc 是一家生物制药公司，专注于开发用于治疗癌症患者的 T 细胞受体  工程化 T 细胞疗法 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227042751abde3a5c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227042751abde3a5c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4539","BK4139","TCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514077581","title":"Tscan Therapeutics, Inc.盘中异动 大幅下跌5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514077581","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514077581?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:54","pubTimestamp":1740412493,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时54分，Tscan Therapeutics, Inc.股票出现异动，股价急速下挫5.07%。Tscan Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.10%。其相关个股中，Pepgen Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为233.74%、100.01%、28.36%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 ，振幅分别为151.09%、55.69%、53.34%。Tscan Therapeutics, Inc.公司简介：TScan Therapeutics Inc 是一家生物制药公司，专注于开发用于治疗癌症患者的 T 细胞受体  工程化 T 细胞疗法 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224235454962eac23&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224235454962eac23&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","TCRX","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513101218","title":"Tscan Therapeutics, Inc.盘中异动 急速拉升5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513101218","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513101218?lang=zh_cn&edition=full","pubTime":"2025-02-22 01:19","pubTimestamp":1740158358,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日01时19分，Tscan Therapeutics, Inc.股票出现异动，股价急速拉升5.02%。Tscan Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.45%。其相关个股中，Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Osr Holdings, Inc.、Invivyd, Inc.涨幅较大，Nkgen Biotech, Inc.、Aditxt, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为239.47%、222.36%、128.50%，振幅较大的相关个股有Osr Holdings, Inc.、Osr Holdings Inc C/Wts 09/02/2028 、Nkgen Biotech, Inc.，振幅分别为72.46%、57.50%、48.35%。Tscan Therapeutics, Inc.公司简介：TScan Therapeutics Inc 是一家生物制药公司，专注于开发用于治疗癌症患者的 T 细胞受体  工程化 T 细胞疗法 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222011919a24ed4eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222011919a24ed4eb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TCRX","BK4139","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512482724","title":"Tscan Therapeutics, Inc.盘中异动 临近午盘急速拉升5.44%报2.12美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512482724","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512482724?lang=zh_cn&edition=full","pubTime":"2025-02-20 00:32","pubTimestamp":1739982748,"startTime":"0","endTime":"0","summary":"北京时间2025年02月20日00时32分，Tscan Therapeutics, Inc.股票出现异动，股价急速拉升5.44%。Tscan Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.47%。其相关个股中，Osr Holdings, Inc.、Osr Holdings Inc C/Wts 02/09/2028 、Neurosense Therapeutics Ltd C/Wts 10/11/2026 涨幅较大，Aditxt, Inc.、Alzamend Neuro, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为587.85%、244.73%、197.64%，振幅较大的相关个股有Osr Holdings Inc C/Wts 02/09/2028 、Osr Holdings, Inc.、Aditxt, Inc.，振幅分别为207.68%、159.49%、48.18%。Tscan Therapeutics, Inc.公司简介：TScan Therapeutics Inc 是一家生物制药公司，专注于开发用于治疗癌症患者的 T 细胞受体  工程化 T 细胞疗法 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220003228988b44bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220003228988b44bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4539","TCRX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512160456","title":"Tscan Therapeutics, Inc.盘中异动 股价大涨5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512160456","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512160456?lang=zh_cn&edition=full","pubTime":"2025-02-19 00:38","pubTimestamp":1739896697,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日00时38分，Tscan Therapeutics, Inc.股票出现异动，股价大幅上涨5.12%。Tscan Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.58%。其相关个股中，Estrella Immunopharma Inc C/Wts 29/09/2028、Solid Biosciences Inc.、Ocean Biomedical Inc C/Wts 14/02/2028 涨幅较大，Aditxt, Inc.、Moleculin Biotech, Inc.、Solid Biosciences Inc.较为活跃，换手率分别为395.73%、179.58%、150.74%，振幅较大的相关个股有Estrella Immunopharma Inc C/Wts 29/09/2028、Abvc Biopharma, Inc.、Allogene Therapeutics, Inc.，振幅分别为148.75%、92.00%、79.17%。Tscan Therapeutics, Inc.公司简介：TScan Therapeutics Inc 是一家生物制药公司，专注于开发用于治疗癌症患者的 T 细胞受体  工程化 T 细胞疗法 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219003817abd3ca90&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219003817abd3ca90&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TCRX","BK4139","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tscan.com","stockEarnings":[{"period":"1week","weight":-0.1816},{"period":"1month","weight":-0.5855},{"period":"3month","weight":-0.6487},{"period":"6month","weight":-0.6949},{"period":"1year","weight":-0.8268},{"period":"ytd","weight":-0.6796}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0106},{"period":"3month","weight":0.0304},{"period":"6month","weight":0.154},{"period":"1year","weight":0.1622},{"period":"ytd","weight":0.1208}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"TScan Therapeutics, Inc.于2018年4月17日在特拉华州注册成立。该公司是一家临床前阶段的生物制药公司，专注于开发强大的T细胞受体工程T细胞或TCR-T疗法，用于治疗癌症患者。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.002115},{"month":2,"riseRate":0.6,"avgChangeRate":0.133544},{"month":3,"riseRate":0.2,"avgChangeRate":-0.16704},{"month":4,"riseRate":0.6,"avgChangeRate":0.026532},{"month":5,"riseRate":0.6,"avgChangeRate":0.08622},{"month":6,"riseRate":0.4,"avgChangeRate":-0.064907},{"month":7,"riseRate":0.6,"avgChangeRate":0.094093},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.098247},{"month":9,"riseRate":0.5,"avgChangeRate":-0.090401},{"month":10,"riseRate":0.6,"avgChangeRate":0.083419},{"month":11,"riseRate":0.4,"avgChangeRate":-0.001328},{"month":12,"riseRate":0,"avgChangeRate":-0.252784}],"exchange":"NASDAQ","name":"Tscan Therapeutics, Inc.","nameEN":"Tscan Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tscan Therapeutics, Inc.(TCRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Tscan Therapeutics, Inc.(TCRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Tscan Therapeutics, Inc.,TCRX,Tscan Therapeutics, Inc.股票,Tscan Therapeutics, Inc.股票老虎,Tscan Therapeutics, Inc.股票老虎国际,Tscan Therapeutics, Inc.行情,Tscan Therapeutics, Inc.股票行情,Tscan Therapeutics, Inc.股价,Tscan Therapeutics, Inc.股市,Tscan Therapeutics, Inc.股票价格,Tscan Therapeutics, Inc.股票交易,Tscan Therapeutics, Inc.股票购买,Tscan Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tscan Therapeutics, Inc.(TCRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Tscan Therapeutics, Inc.(TCRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}